Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Revolution Medicines

Revolution Medicines

RVMD

0.00

Mizuho analyst Joseph Catanzaro maintains Revolution Medicines (NASDAQ: RVMD) with a Outperform and raises the price target from $185 to $215.